Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 3/20 | 1.00 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.74 |
| ▸ | OSBP | P22059 | 3/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
| ▸ | RORC | P51449 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.70 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.70 |
| ▸ | NPC1L1 | Q9UHC9 | 4/20 | 0.69 |
| ▸ | CDC25A | P30304 | 1/20 | 0.64 |
| ▸ | GBA1 | P04062 | 2/20 | 0.63 |
| ▸ | UGCG | Q16739 | 2/20 | 0.63 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.63 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.63 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15110118 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL587902 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL587901 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL13147079 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL1708156 | 1.00 | POLA1 (1.00) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL15398207 | 0.93 | POLA1 (0.87) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL12947846 | 0.93 | POLA1 (0.87) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL5009864 | 0.93 | POLA1 (0.86) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL16790328 | 0.93 | POLA1 (0.86) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL2474688 | 0.93 | POLA1 (0.86) | POLA1CYP46A1OSBPUSP2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200354394-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | AKAMARA THERAPEUTICS INC (US) | 2020-11-12 | — | — | US | disclosed |
| US-10730899-B2 | Lipid-based platinum compounds and nanoparticles | Akamara Therapeutics, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10426753-B2 | Supramolecular combinatorial therapeutics | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2019-10-01 | — | — | US | disclosed |
| US-20190002489-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | AKAMARA THERAPEUTICS INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20170112800-A1 | SUPRAMOLECULAR COMBINATORIAL THERAPEUTICS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112800-A1 | SUPRAMOLECULAR COMBINATORIAL THERAPEUTICS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-04-27 | — | — | US | disclosed |
| US-9393200-B2 | Lipopolyamines of spermine type for construction of liposomal transfection systems | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2016-07-19 | — | — | US | disclosed |
| US-9393200-B2 | Lipopolyamines of spermine type for construction of liposomal transfection systems | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2016-07-19 | — | — | US | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
| US-20160145284-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145284-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2016-05-26 | — | — | US | disclosed |
| WO-2015153345-A1 | SUPRAMOLECULAR COMBINATORIAL THERAPEUTICS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2015-10-08 | — | — | WO | disclosed |
| WO-2014201376-A2 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112800-A1 | SUPRAMOLECULAR COMBINATORIAL THERAPEUTICS | PDCD1LG2, PDCD1, ERBB3 | POLA1 3019/4885CYP46A1 2429/4885OSBP 2179/4885 |
| US-10730899-B2 | Lipid-based platinum compounds and nanoparticles | SGMS1, SGMS2, PHOSPHO1 | POLA1 2085/4885CYP46A1 1184/4885OSBP 645/4885 |
| US-20200354394-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | SGMS1, SGMS2, PHOSPHO1 | POLA1 2085/4885CYP46A1 1184/4885OSBP 645/4885 |
| US-20160145284-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | SGMS1, SGMS2, PHOSPHO1 | POLA1 2085/4885CYP46A1 1184/4885OSBP 645/4885 |
| US-10426753-B2 | Supramolecular combinatorial therapeutics | PDCD1LG2, PDCD1, ERBB3 | POLA1 3019/4885CYP46A1 2429/4885OSBP 2179/4885 |
| US-20190002489-A1 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES | SGMS1, SGMS2, PHOSPHO1 | POLA1 2085/4885CYP46A1 1184/4885OSBP 645/4885 |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | POLA1 3737/4885CYP46A1 2630/4885OSBP 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.